Tenaya Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Tenaya Therapeutics R&D Spending Growth & History (TNYA)
Tenaya Therapeutics's r&d spending was $68.6M for fiscal 2025.
View full Tenaya Therapeutics company overviewTenaya Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $68.6M | −$18.1M | −20.91% |
| 2024 | 2024-12-31 | $86.7M | −$11.3M | −11.52% |
| 2023 | 2023-12-31 | $98.0M | $3.5M | +3.70% |
| 2022 | 2022-12-31 | $94.5M | $40.1M | +73.80% |
| 2021 | 2021-12-31 | $54.4M | $23.3M | +74.90% |
| 2020 | 2020-12-31 | $31.1M | — | — |
Tenaya Therapeutics quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $16.6M | −$767,000 | −4.42% |
| Q1 2026 | 2026-03-31 | $14.8M | −$6.2M | −29.57% |
| Q4 2025 | 2025-12-31 | $14.8M | −$3.9M | −20.82% |
| Q3 2025 | 2025-09-30 | $15.4M | −$5.0M | −24.51% |
| Q2 2025 | 2025-06-30 | $17.4M | −$5.3M | −23.31% |
| Q1 2025 | 2025-03-31 | $21.1M | −$4.0M | −15.88% |
| Q4 2024 | 2024-12-31 | $18.7M | −$4.2M | −18.27% |
| Q3 2024 | 2024-09-30 | $20.4M | −$2.7M | −11.87% |
| Q2 2024 | 2024-06-30 | $22.6M | −$3.8M | −14.46% |
| Q1 2024 | 2024-03-31 | $25.1M | −$550,000 | −2.15% |
| Q4 2023 | 2023-12-31 | $22.9M | −$2.9M | −11.20% |
| Q3 2023 | 2023-09-30 | $23.1M | −$667,000 | −2.81% |
| Q2 2023 | 2023-06-30 | $26.5M | $5.6M | +26.83% |
| Q1 2023 | 2023-03-31 | $25.6M | $1.4M | +6.00% |
| Q4 2022 | 2022-12-31 | $25.7M | $4.8M | +22.88% |
| Q3 2022 | 2022-09-30 | $23.8M | $10.8M | +83.54% |
| Q2 2022 | 2022-06-30 | $20.9M | $10.0M | +91.42% |
| Q1 2022 | 2022-03-31 | $24.2M | $14.6M | +151.88% |
| Q4 2021 | 2021-12-31 | $21.0M | — | — |
| Q3 2021 | 2021-09-30 | $12.9M | $4.5M | +52.64% |
| Q2 2021 | 2021-06-30 | $10.9M | $3.9M | +56.74% |
| Q1 2021 | 2021-03-31 | $9.6M | — | — |
| Q3 2020 | 2020-09-30 | $8.5M | — | — |
| Q2 2020 | 2020-06-30 | $7.0M | — | — |
Tenaya Therapeutics r&d spending trends
Over the last five fiscal years, Tenaya Therapeutics's r&d spending increased from $31.1M to $68.6M, a change of $37.5M. The latest reported quarter, Q2 2026, shows $16.6M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tenaya Therapeutics source filings ↗